復星醫藥(02196.HK)與重藥控股簽訂有關原材料/產品及服務的互供框架協議
格隆匯6月9日丨復星醫藥(02196.HK)發佈公吿,2021年6月9日,公司與重藥控股股份有限公司簽訂《有關原材料/產品及服務的互供框架協議》。同日,公司與復星國際有限公司簽訂《房屋租賃及物業服務框架協議》(包括涉及房屋承租、出租業務的協議各1份,以下合稱“《租賃框架協議》”)及《產品和服務互供框架協議》。
公司表示,該等框架協議系公司與關聯方以自願、平等、互利、公允為原則,以市場價格為基礎簽訂;簽訂該等框架協議有利於提升集團運營效率,不存在損害公司及非關聯股東利益的情形,不影響公司的獨立性。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.